News ArticleAnthem Biosciences Achieves 7.9% Revenue Growth and 50.6% EBITDA Margin in Q2FY27
Company reports ₹5,940 million revenue with strong CRDMO segment and ₹2,115 million PAT for quarter ended September 30, 2026
Anthem Biosciences Limited announced a 7.9% year-on-year revenue increase to ₹5,940 million for the quarter ended September 30, 2026, driven by a 9.2% rise in its CRDMO segment. The company posted an EBITDA margin of 50.6% and a profit after tax of ₹2,115 million, reflecting improved profitability and operational efficiency. For the half year ended September 30, 2026, the firm reported revenues of ₹10,123 million and a net cash position of ₹15,380 million.
Anthem Biosciences Limited
Investor Presentation
Anthem Biosciences Limited posted a 7.9% year-over-year increase in consolidated revenue to ₹5,940 million for the quarter ended September 30, 2026. The Clinical Research Development and Manufacturing Organization (CRDMO) segment led growth with a 9.2% rise in revenues. The company also improved profitability, reporting an EBITDA margin of 50.6% and a profit after tax (PAT) of ₹2,115 million during the quarter.
Total consolidated revenues for Q2FY27 stood at ₹6,529 million including other income, growing 9.1% year-over-year. The CRDMO segment generated ₹5,093 million, accounting for over 85% of revenues, while Specialty Ingredients contributed ₹848 million.
EBITDA for the quarter increased 24.1% year-over-year to ₹3,304 million, reflecting disciplined cost management and operational efficiencies. EBITDA margins expanded by 610 basis points to 50.6%.
Profit before tax rose 29.1% to ₹2,964 million with a PAT margin improvement to 32.4%. The net cash position at quarter end was ₹15,380 million, strengthening the company’s financial flexibility.
For the half year ended September 30, 2026, Anthem Biosciences recorded revenues of ₹10,123 million with an EBITDA margin of 46.2% and PAT of ₹3,314 million. The company’s net cash stood at ₹15,380 million as of September 30, 2026.
Highlights
- Q2FY27 consolidated revenues of ₹5,940 million, up 7.9% year-over-year
- CRDMO segment revenues increased 9.2% to ₹5,093 million in Q2FY27
- EBITDA margin expanded to 50.6%, a 610 basis point improvement year-over-year
- Profit after tax for Q2FY27 reached ₹2,115 million with 32.4% PAT margin
- Half year revenues ₹10,123 million, PAT of ₹3,314 million and net cash of ₹15,380 million as of September 30, 2026
Key Data Snapshot
Financial performance
- Anthem Biosciences reported consolidated revenue from operations of ₹5,940 million for Q2FY27, a 7.9% increase year-over-year.
- The CRDMO segment contributed ₹5,093 million in revenues, representing 85.7% of the total for the quarter.
- Specialty Ingredients segment revenues were ₹848 million, about 14.3% of total Q2FY27 revenues.
- EBITDA increased 24.1% year-over-year to ₹3,304 million, with margins expanding by 610 basis points to 50.6%.
- Profit after tax for Q2FY27 was ₹2,115 million, improving 21.9% compared to the same period last year.
- For the half year (H1FY27), consolidated revenues were ₹10,123 million with EBITDA margins of 46.2% and PAT margins of 30.2%.
- The company's net cash position as of September 30, 2026, was ₹15,380 million, supporting a strong balance sheet position.
Strategic context
- The company’s performance in Q2FY27 was driven primarily by the strong demand in the CRDMO business segment.
- Operational efficiencies and cost discipline contributed to margin expansion and improved profitability.
- Anthem Biosciences continues to maintain a strong return profile with ROE of 26.8% and post-tax ROCE of 50.3% in Q2FY27.
Management commentary
- Chairman, MD and CEO Ajay Bhardwaj expressed confidence in sustaining growth and long-term value creation.
- Management highlighted continued underlying demand and focus on cost efficiencies, yield optimization, and workforce productivity.
- The company expects to maintain its industry-leading margins throughout the year.
Regulatory and governance context
- The earnings call presentation and related information were disclosed in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The company’s disclosures include unaudited consolidated financial results for the quarter and half year ended September 30, 2026.
Highlights
- Q2FY27 consolidated revenues of ₹5,940 million, up 7.9% year-over-year
- CRDMO segment revenues increased 9.2% to ₹5,093 million in Q2FY27
- EBITDA margin expanded to 50.6%, a 610 basis point improvement year-over-year
- Profit after tax for Q2FY27 reached ₹2,115 million with 32.4% PAT margin
- Half year revenues ₹10,123 million, PAT of ₹3,314 million and net cash of ₹15,380 million as of September 30, 2026
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Multi Commodity Exchange of India Ltd Reports Nearly 100% Increase in Total Income for H1 FY27 with ₹1,603 Crore
Multi Commodity Exchange of India Ltd (MCX) reported total income of ₹1,603 crore for the half year ended September 30, 2026, nearly doubling the ₹807 crore recorded in the same period last year. Profit after tax reached ₹868 crore, showcasing substantial financial growth.
Read Full Story
GlaxoSmithKline India Achieves 21% Revenue Growth in Q2 FY27 with Innovation-Driven Portfolio Expansion
GlaxoSmithKline Pharmaceuticals Limited reported a 21% revenue increase to ₹1180 crore in Q2 FY27, driven by strong sales execution and a rising contribution from its innovation portfolio which grew to 7% of total sales. The company sustained market leadership with a 25% share in its representative market amid competitive industry growth.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 mn Revenue in Q2 FY27 with 29% YoY Growth Bolstered by India Formulations
Zydus Lifesciences Limited recorded a 29% year-on-year increase in revenues to Rs. 79,096 million during the second quarter of fiscal year 2027, driven primarily by robust growth in their India branded formulations and North America markets.
Read Full Story
